专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011038061A2 NOVEL NPR-B AGONISTS 审中-公开
公开(公告)号：WO2011038061A2
公开(公告)日：2011-03-31
申请号：PCT/US2010/049912
申请日：2010-09-23
申请人： ALCON RESEARCH, LTD. , OSTERKAMP, Frank , HAWLISCH, Heiko , HUMMEL, Gerd , KNAUTE, Tobias , REIMER, Ulf , REINEKE, Ulrich , RICHTER, Uwe , SIMON, Bernadett , SPECKER, Edgar , WOISCHNIK, Markus , HELLBERG, Mark R.
发明人： OSTERKAMP, Frank , HAWLISCH, Heiko , HUMMEL, Gerd , KNAUTE, Tobias , REIMER, Ulf , REINEKE, Ulrich , RICHTER, Uwe , SIMON, Bernadett , SPECKER, Edgar , WOISCHNIK, Markus , HELLBERG, Mark R.
IPC分类号： C07K7/06
CPC分类号： C07K7/06 , C07K7/02 , C07K7/08
摘要： Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D- amino acid residues connected to one another via peptide bonds.
摘要翻译：公开了具有NPR-B激动剂活性的新型化合物。优选的化合物是含有8-13个通过肽键相互连接的常规或非常规L-或D-氨基酸残基的线性肽。

2. 发明申请

WO2010071894A2 TFPI INHIBITORS AND METHODS OF USE 审中-公开
标题翻译： TFPI抑制剂及其使用方法
公开(公告)号：WO2010071894A2
公开(公告)日：2010-06-24
申请号：PCT/US2009069060
申请日：2009-12-21
申请人： BAXTER INT , BAXTER HEALTHCARE SA , 3B PHARMACEUTICALS GMBH , COSMIX MOLECULAR BIOLOG GMBH , DOCKAL MICHAEL , EHRLICH HARTMUT , SCHEIFLINGER FRIEDRICH , REIMER ULF , REINEKE ULRICH , POLAKOWSKI THOMAS , SCHNEIDER EBERHARD
发明人： DOCKAL MICHAEL , EHRLICH HARTMUT , SCHEIFLINGER FRIEDRICH , REIMER ULF , REINEKE ULRICH , POLAKOWSKI THOMAS , SCHNEIDER EBERHARD
IPC分类号： A61K38/10 , A61P7/02 , C07K7/08
CPC分类号： C07K14/4703 , A61K38/00 , A61K47/551 , A61K47/557 , A61K47/60 , C07K7/08 , C07K14/001
摘要： The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.
摘要翻译：本发明提供了结合组织因子途径抑制剂（TFPI）（包括TFPI抑制肽）及其组合物的肽。肽可以用于抑制TFPI，增强凝血因子缺陷受试者中的凝血酶形成，增加受试者中的血块形成和/或治疗受试者的血液凝固障碍。

3. 发明申请

WO2007131764A2 NEW HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF 审中-公开
标题翻译：用于抑制整合及其使用的新型杂环化合物
公开(公告)号：WO2007131764A2
公开(公告)日：2007-11-22
申请号：PCT/EP2007/004283
申请日：2007-05-14
申请人： JERINI AG , ZISCHINSKY, Gunther , STRAGIES, Roland , OSTERKAMP, Frank , SCHARN, Dirk , HUMMEL, Gerd , KALKHOF, Holger , ZAHN, Grit , VOSSMEYER, Dörte , CHRISTNER-ALBRECHT, Claudia , REINEKE, Ulrich
发明人： ZISCHINSKY, Gunther , STRAGIES, Roland , OSTERKAMP, Frank , SCHARN, Dirk , HUMMEL, Gerd , KALKHOF, Holger , ZAHN, Grit , VOSSMEYER, Dörte , CHRISTNER-ALBRECHT, Claudia , REINEKE, Ulrich
IPC分类号： C07D401/12 , C07D403/12 , C07D407/12 , C07D409/12 , C07D413/12 , C07D417/12 , A61P29/00 , A61K31/44
CPC分类号： C07D405/12 , C07D401/12 , C07D403/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要： The present invention is related to a compound of formula (I), wherein A is a radical selected from the group comprising aromatic heterocyclic 5-membered ring systems; Ar is a radical selected from the group comprising optionally substituted 5- and 6-membered aromatic ring systems, whereby the ring system contains 0, 1, 2 or 3 heteroatoms selected from the group comprising N, O and S; Z is a radical individually and independently selected from the group comprising (CH 2 ) n -E-(CH 2 ) m -L-(CH 2 ) k and (CH 2 ) m -L-(CH 2 ) k, wherein E is a radical which is either absent or present, whereby if E is present, E is selected from the group comprising O, S, NH, NR a , CO, SO, SO 2 , acetylene and substituted ethylene; L is a radical which is either absent or present, whereby if L is present, L is individually and independently selected from the group comprising O, S, NH, NR b , CO, SO, SO 2 , substituted ethylene and acetylene; and k, m and n are individually and independently O, 1, 2 or 3; ψ is a radical of formula (II), wherein Q is a radical selected from the group comprising a direct bond, Cl-C4alkyl, C=O, C=S, O, S, CR a R b , NR a -NR b , N=N, CR a =N, N=CR a , (C=O)-O, 0-(C=O), SO 2 , NR a , (C=O)-NR 3 , NR a -(C=0)-NR b , NR C -(C=O), 0-(C=0)-NR c , NR c -(C=0)-0, NR C -(C=S), (C=S)-NR c , NR c -(C=S)-NR d , NR C -SO 2 and SO 2 -NR c . R1, R a , R b , R c and R d are radicals which are individually and independently selected from the group comprising H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocycloyl, substituted heterocycloyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, alkyloxy, alkyloxyalkyl, substituted alkyloxyalkyl, alkyloxycycloalkyl, substituted alkyloxycycloalkyl, alkyloxyheterocyclyl, substituted alkyloxyheterocyclyl, alkyloxyaryl, substituted alkyloxyaryl, alkyloxyheteroaryl, substituted alkyloxyheteroaryl, alkylthioalkyl, substituted alkylthioalkyl, alkylthiocycloalkyl and substituted alkylthiocycloalkyl, hydroxy, substituted hydroxy, oxo, thio, substituted thio, aminocarbonyl, substituted aminocarbonyl, formyl, substituted formyl, thioformyl, substituted thioformyl, amino, substituted amino, hydroxy 1, substituted hydroxy 1, mercapto, substituted mercapto, hydrazino, substituted hydrazino, diazene, substituted diazene, imine, substituted imine, amidino, substituted amidino, iminomethylamino, substituted iminomethylamino, ureido, substituted ureido, formylamino, substituted formylamino, aminocarbonyloxy, substituted aminocarbonyloxy, hydroxycarbonylamino, substituted hydroxycarbonylamino, hydroxycarbonyl, substituted hydroxycarbonyl, formyloxy, substituted formyloxy, thioformylamino, substituted thioformylamino, aminothiocarbonyl, substituted aminothiocarbonyl, thioureido, substituted thioureido, sufonyl, substituted sulfonyl, sulfonamino, substituted sulfonamino, aminosulfonyl, substituted aminosulfonyl, cyano and halogen; R 2 is a hydrophobic moiety; R 3 is a radical selected from the group comprising OH, C1C8alkyloxy and aryl C0-C6alkyloxy; R 4 is a radical selected from the group comprising hydrogen, halogen and C1-C4alkyl; and G is a radical containing a basic moiety.
摘要翻译：本发明涉及式（I）化合物，其中A是选自芳族杂环5元环系的基团; Ar是选自包含任选取代的5元和6元芳族环系的基团，其中该环体系含有0,1,2或3个选自N，O和S的杂原子; Z是单独且独立地选自下列基团的基团：（CH 2 CH 2）n - （CH 2） /（CH 2）2 - （CH 2）n - （CH 2）其中E是不存在或存在的基团，由此如果存在E，则E选自O，S，NH，NR CO，SO，SO 2，乙炔和取代的乙烯; L是不存在或存在的基团，其中如果存在L，则L独立地且独立地选自O，S，NH，NR b，CO，SO，SO， > 2，取代的乙烯和乙炔; 并且k，m和n各自独立地为O，1,2或3; ？是式（II）的基团，其中Q是选自直接键，C 1 -C 4烷基，C = O，C = S，O，S，CR a， N，N = N，CR = N，N = CR，（C = O）-O，O-（C = O），SO 2，NR a，（C = O）（C = O）-NR b，C（O） - （C = O），（C = O）-NR C，C（O）C（= C）），（C = S）-NR C C， - NR C - （C = S）-NR D， SO 2 SO 2和SO 2 -NR 2 C 0。 R 1，R a，B，R b，R c和R d都是独立地且独立地选自包括H，烷基，取代的烷基，环烷基，取代的环烷基，杂环基，取代的杂环基，芳基，取代的芳基，杂芳基，取代的杂芳基，芳基烷基，取代的芳基烷基，杂芳基烷基，取代的杂芳基烷基，环烷基烷基，取代的环烷基烷基，杂环基烷基，取代的杂环基烷基，烷基氧基烷基，烷氧基烷基，取代烷氧基环烷基，烷氧基杂环基，取代烷氧基杂环基，烷氧基芳基，取代烷氧基芳基，烷氧基杂芳基，取代烷氧基杂芳基，烷硫基烷基，取代烷硫基烷基，烷硫基环烷基和取代烷硫基环烷基，羟基，取代羟基，氧代，取代的氨基羰基，甲酰基，取代的甲酰基，硫代甲酰基，取代基氨基，取代的氨基，羟基1，取代的羟基1，巯基，取代的巯基，肼基，取代的肼基，二氮烯，取代的二嗪，亚胺，取代的亚胺，脒基，取代的脒基，亚氨基甲基氨基，取代的亚氨基甲基氨基，脲基，取代的脲基，甲酰氨基，取代的甲酰氨基，氨基羰基氧基，取代的氨基羰基氧基，羟基羰基氨基，取代的羟基羰基氨基，羟基羰基，取代的羟基羰基，甲酰氧基，取代的甲酰氧基，硫代甲酰氨基，取代的硫代甲酰基氨基，氨基硫代羰基，取代的氨基硫代羰基，硫脲基，取代的硫脲基，磺酰基，取代的磺酰基，磺氨基，取代的磺氨基，氨基磺酰基，取代氨基磺酰基，氰基和卤素; R 2是疏水部分; R 3是选自OH，C 1 -C 8烷氧基和芳基C 0 -C 6烷氧基的基团; R 4是选自氢，卤素和C 1 -C 4烷基的基团; 并且G是含有基本部分的基团。

4. 发明申请

WO2007088041A1 COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF 审中-公开
标题翻译：用于抑制整合及其使用的化合物
公开(公告)号：WO2007088041A1
公开(公告)日：2007-08-09
申请号：PCT/EP2007/000832
申请日：2007-01-31
申请人： JERINI AG , ZISCHINSKY, Gunther , STRAGIES, Roland , OSTERKAMP, Frank , SCHARN, Dirk , HUMMEL, Gerd , KALKHOF, Holger , ZAHN, Grit , VOSSMEYER, Dörte , CHRISTNER-ALBRECHT, Claudia , REINEKE, Ulrich
发明人： ZISCHINSKY, Gunther , STRAGIES, Roland , OSTERKAMP, Frank , SCHARN, Dirk , HUMMEL, Gerd , KALKHOF, Holger , ZAHN, Grit , VOSSMEYER, Dörte , CHRISTNER-ALBRECHT, Claudia , REINEKE, Ulrich
IPC分类号： C07D401/12 , C07D471/04 , A61K31/4545 , A61P35/00
CPC分类号： C07D401/12 , C07D471/04
摘要： The present invention is related to a compound of formula (I), wherein A is a nonaromatic heterocyclic ring., Ar is either absent or phenylene; Ψ is a radical of formula (II), R 2 is a hydrophobic moiety; and G is a radical containing one or more moieties selected from the group consisting of NH, OH and a basic moiety. The compounds are inhibitors of integrins, especially antagonists of the fibronectin receptor alpha5beta1, useful as anti-angiogenic agents.
摘要翻译：本发明涉及式（I）化合物，其中A是非芳族杂环，Ar不存在或亚苯基; ？是式（II）的基团，R 2是疏水部分; 并且G是含有一个或多个选自NH，OH和碱性部分的部分的基团。化合物是整联蛋白的抑制剂，特别是纤连蛋白受体α5β1的拮抗剂，可用作抗血管生成剂。

5. 发明申请

WO2007003411A3 KININ ANTAGONISTS FOR TREATING BLADDER DYSFUNCTION 审中-公开
标题翻译：用于处理刀片功能的KININ ANTAGONISTS
公开(公告)号：WO2007003411A3
公开(公告)日：2007-05-18
申请号：PCT/EP2006006504
申请日：2006-07-04
申请人： JERINI AG , GIBSON CHRISTOPH , HUMMEL GERD , KNOLLE JOCHEN , REINEKE ULRICH , TRADLER THOMAS
发明人： GIBSON CHRISTOPH , HUMMEL GERD , KNOLLE JOCHEN , REINEKE ULRICH , TRADLER THOMAS
IPC分类号： A61K45/00 , A61K38/08 , A61P13/10
CPC分类号： A61K38/08 , A61K45/06
摘要： The present invention is related to the use of a kinin receptor antagonist for the manufacture of a medicament for the treatment and/or prevention of bladder dysfunction, whereby the kinin receptor is selected from the group comprising Bl and B2 receptors.
摘要翻译：本发明涉及激肽受体拮抗剂在制备用于治疗和/或预防膀胱功能障碍的药物中的用途，其中激肽受体选自B1和B2受体。

6. 发明申请

WO2011115712A2 TFPI INHIBITORS AND METHODS OF USE 审中-公开
标题翻译： TFPI抑制剂及其使用方法
公开(公告)号：WO2011115712A2
公开(公告)日：2011-09-22
申请号：PCT/US2011/024604
申请日：2011-02-11
申请人： BAXTER INTERNATIONAL INC , BAXTER HEAL THCARE S.A. , 3B PHARMACEUTICALS GMBH , DOCKAL, Michael , HARTMANN, Rudolf , FRIES, Markus , SCHEIFLINGER, Friedrich , EHRLICH, Hartmut , REINEKE, Ulrich , OSTERKAMP, Frank , POLAKOWSKI, Thomas
发明人： DOCKAL, Michael , HARTMANN, Rudolf , FRIES, Markus , SCHEIFLINGER, Friedrich , EHRLICH, Hartmut , REINEKE, Ulrich , OSTERKAMP, Frank , POLAKOWSKI, Thomas
IPC分类号： A61K38/18
CPC分类号： A61K38/10 , A61K38/00 , A61K2121/00 , C07K1/14 , C07K7/08 , C07K14/00 , C07K14/8114 , G01N33/68 , G01N2333/745 , G01N2333/8114 , G01N2333/96444 , G01N2333/96447 , G01N2500/02 , G01N2500/04 , G01N2500/20 , G06F19/16 , G06F19/18
摘要： The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
摘要翻译：本发明提供了结合组织因子途径抑制剂（TFPI），包括TFPI抑制肽的肽及其组合物。肽可以用于抑制TFPI，增强凝血因子缺陷受试者中的凝血酶形成，增加受试者中的血块形成，治疗受试者的血液凝固障碍，纯化TFPI和鉴定TFPI结合化合物。

7. 发明申请

WO2011075471A2 NOVEL NPR-B AGONISTS AND METHODS OF USE FOR THE TREATMENT OF C-TYPE NATRIURETIC PEPTIDE-MEDIATED DISORDERS 审中-公开
标题翻译：新型NPR-B激动剂和治疗C型脑脊液介导性疾病的方法
公开(公告)号：WO2011075471A2
公开(公告)日：2011-06-23
申请号：PCT/US2010/060263
申请日：2010-12-14
申请人： ALCON RESEARCH, LTD. , OSTERKAMP, Frank , HAWLISCH, Heiko , HUMMEL, Gerd , KNAUTE, Tobias , REIMER, Ulf , REINEKE, Ulrich , SIMON, Bernadett , RICHTER, Uwe , SPECKER, Edgar , WOISCHNIK, Markus
发明人： OSTERKAMP, Frank , HAWLISCH, Heiko , HUMMEL, Gerd , KNAUTE, Tobias , REIMER, Ulf , REINEKE, Ulrich , SIMON, Bernadett , RICHTER, Uwe , SPECKER, Edgar , WOISCHNIK, Markus
IPC分类号： A61K38/08
CPC分类号： A61K38/08 , A61K38/2242
摘要： Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D- amino acid residues connected to one another via peptide bonds. Also disclosed are methods of treating C-type natriuretic peptide (CNP)-mediated disorders, including glaucoma and/or elevated intraocular pressure, in a subject using pharmaceutical compositions that include a novel NPR-B agonist as described herein.
摘要翻译：公开了具有NPR-B激动活性的新化合物。优选的化合物是含有通过肽键相互连接的8-13个常规或非常规的L-或D-氨基酸残基的线性肽。还公开了使用包含如本文所述的新型NPR-B激动剂的药物组合物治疗受试者的C型利钠肽（CNP）介导的疾病（包括青光眼和/或升高的眼内压）的方法。

8. 发明申请

WO2010031589A1 SMALL MOLECULE BRADYKININ B2 RECEPTOR MODULATORS 审中-公开
标题翻译：小分子BRADYKININ B2受体调节剂
公开(公告)号：WO2010031589A1
公开(公告)日：2010-03-25
申请号：PCT/EP2009/006842
申请日：2009-09-22
申请人： JERINI AG , GIBSON, Christoph , SCHNATBAUM, Karsten , TRADLER, Thomas , PFEIFER, Jochen , SCHARN, Dirk , REIMER, Ulf , RICHTER, Uwe , HUMMEL, Gerd , REINEKE, Ulrich , LOCARDI, Elsa , PASCHKE, Matthias
发明人： GIBSON, Christoph , SCHNATBAUM, Karsten , TRADLER, Thomas , PFEIFER, Jochen , SCHARN, Dirk , REIMER, Ulf , RICHTER, Uwe , HUMMEL, Gerd , REINEKE, Ulrich , LOCARDI, Elsa , PASCHKE, Matthias
IPC分类号： C07D401/14 , C07D417/14 , A61K31/47 , A61P17/00
CPC分类号： C07D401/14 , C07D413/14 , C07D417/14
摘要： The present invention is related to a compound of the formula (I): or a pharmacologically acceptable salt, solvate, or hydrate thereof, wherein R 1 is: (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o), (p), (q), (r), (s); R 2 is C1, F, or methoxy; R 3 is methyl, methoxy, hydroxymethyl, H, or absent; R 4 is methyl, ethyl, HO, H, or absent; A 1 is C or N; A 2 is C or N; R 6 is H or OH; R 5 is: (t), (u), (v), (w), (x), (y), (z).
摘要翻译：本发明涉及式（I）化合物或其药理学上可接受的盐，溶剂化物或水合物，其中R1为：（a），（b），（c），（d），（e），（g），（h），（i），（j），（k），（l），（m），（n），（o），（p），（q） r），（s）; R2是C1，F或甲氧基; R3是甲基，甲氧基，羟甲基，H或不存在; R4是甲基，乙基，HO，H或不存在; A1为C或N; A2为C或N; R6是H或OH; R5是：（t），（u），（v），（w），（x），（y），（z）。

9. 发明申请

WO2009036996A2 SMALL MOLECULE BRADYKININ B1 RECEPTOR ANTAGONISTS 审中-公开
标题翻译：小分子BRADYKININ B1受体拮抗剂
公开(公告)号：WO2009036996A2
公开(公告)日：2009-03-26
申请号：PCT/EP2008007919
申请日：2008-09-19
申请人： JERINI AG , LOCARDI ELSA , DINKEL KLAUS , SCHAUDT MARCO , RICHTER UWE , SCHARN DIRK , HUMMEL GERD , REINEKE ULRICH , REIMER ULF
发明人： LOCARDI ELSA , DINKEL KLAUS , SCHAUDT MARCO , RICHTER UWE , SCHARN DIRK , HUMMEL GERD , REINEKE ULRICH , REIMER ULF
IPC分类号： C07D207/06 , A61K31/506 , A61P29/00 , C07C209/00 , C07D207/20 , C07D213/82 , C07D213/89 , C07D239/42 , C07D401/12 , C07D401/14 , C07D403/12 , C07D413/12 , C07D417/12
CPC分类号： C07D403/12 , C07C237/42 , C07C281/06 , C07C2601/02 , C07D207/06 , C07D207/20 , C07D213/82 , C07D213/89 , C07D239/42 , C07D401/12 , C07D401/14 , C07D413/12 , C07D417/12
摘要： Disclosed are compounds of formula (I) which are bradykinin B1 receptor (B1R) antagonists. These compounds are useful to treat diseases or relieve adverse symptoms associated with inflammation and pain. The invention encompasses novel compounds and acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases involving inflammation and pain.
摘要翻译：公开了式（I）化合物，其为缓激肽B1受体（B1R）拮抗剂。这些化合物可用于治疗疾病或缓解与炎症和疼痛相关的不良症状。本发明包括新型化合物及其可接受的衍生物，用于预防和治疗涉及炎症和疼痛的疾病的药物组合物和方法。

10. 发明申请

WO2007131764A3 NEW HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF 审中-公开
标题翻译：用于抑制整合及其使用的新型杂环化合物
公开(公告)号：WO2007131764A3
公开(公告)日：2008-01-10
申请号：PCT/EP2007004283
申请日：2007-05-14
申请人： JERINI AG , ZISCHINSKY GUNTHER , STRAGIES ROLAND , OSTERKAMP FRANK , SCHARN DIRK , HUMMEL GERD , KALKHOF HOLGER , ZAHN GRIT , VOSSMEYER DOERTE , CHRISTNER-ALBRECHT CLAUDIA , REINEKE ULRICH
发明人： ZISCHINSKY GUNTHER , STRAGIES ROLAND , OSTERKAMP FRANK , SCHARN DIRK , HUMMEL GERD , KALKHOF HOLGER , ZAHN GRIT , VOSSMEYER DOERTE , CHRISTNER-ALBRECHT CLAUDIA , REINEKE ULRICH
IPC分类号： C07D401/12 , A61K31/44 , A61P29/00 , C07D403/12 , C07D407/12 , C07D409/12 , C07D413/12 , C07D417/12
CPC分类号： C07D405/12 , C07D401/12 , C07D403/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要： The present invention relates to compounds of formula (I) wherein: A is a radical selected from the group comprising aromatic heterocyclic 5-membered ring systems; Ar is a radical selected from the group comprising optionally substituted 5- and 6-membered aromatic ring systems, whereby the ring system contains 0, 1, 2 or 3 heteroatoms selected from the group comprising N, 0 and S; Z is a linker and ? is a radical of formula (II) and their use for the inhibition of integrin.
摘要翻译：本发明涉及式（I）化合物，其中：A是选自芳族杂环5元环系的基团; Ar是选自包含任选取代的5元和6元芳环体系的基团，其中环系统含有0,1,2或3个选自N，O和S的杂原子; Z是一个连接子？是式（II）的基团及其用于抑制整联蛋白的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式